Date: 2014-09-02
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: F2G (UK)
Product: F901318 (2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]- phenyl}-2-oxo-acetamide)
Action mechanism:
Disease: invasive aspergillosis and other life-threatening fungal infections
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On September 2, 2014, F2G Limited, the antifungal research and development company announced a major milestone in the development of its novel IV/ oral systemic antifungal (F901318) with the commencement of a Phase I clinical study. This study initiates the IV Phase I clinical development of F901318 with the oral programme expected to commence in the near future.
F901318 is being developed by F2G to treat invasive aspergillosis and other life-threatening fungal infections and is of a novel class of antifungals acting against a new cellular target. The discovery and development of F901318 represents a major advance in the treatment of serious fungal disease as currently there are very limited treatment options and resistance to existing drugs is becoming a serious problem. F901318 is highly active against all known azole-resistant aspergilli.
